Last update :
28/04/2024
References   References 3604  
Type : Manufacturer

Research teams :
Authors :
Title : Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Reference : Sanofi Aventis France 2012

Level of Evidence : 
Manufacturer's stability data
Physical stability : 
Chemical stability : 
Other methods : 
Comments : 

List of drugs
InjectionDaunorubicin hydrochloride Anticancer drug
Incompatible + InjectionDexamethasone sodium phosphate
Incompatible + InjectionFludarabine phosphate
Incompatible + InjectionHeparin sodium
Incompatible + InjectionHydrocortisone sodium succinate
Incompatible + InjectionMethylprednisolone acetate
Incompatible + InjectionMethylprednisolone sodium succinate
InjectionDexamethasone sodium phosphate Anti-inflammatory
Incompatible + InjectionDaunorubicin hydrochloride
InjectionFludarabine phosphate Anticancer drug
Incompatible + InjectionDaunorubicin hydrochloride
InjectionHeparin sodium Anticoagulant
Incompatible + InjectionDaunorubicin hydrochloride
InjectionHydrocortisone sodium succinate Anti-inflammatory
Incompatible + InjectionDaunorubicin hydrochloride
InjectionMethylprednisolone acetate Anti-inflammatory
Incompatible + InjectionDaunorubicin hydrochloride
InjectionMethylprednisolone sodium succinate Anti-inflammatory
Incompatible + InjectionDaunorubicin hydrochloride

  Mentions Légales